甘李药业(603087.SH)：前三季度净利润8.18亿元，同比增长61.32%

Core Viewpoint - Ganli Pharmaceutical (603087.SH) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong business performance and growth potential [1] Financial Performance - The total operating revenue for the first three quarters reached 3.047 billion yuan, representing a year-on-year growth of 35.73% [1] - The net profit attributable to shareholders was 818 million yuan, showing a year-on-year increase of 61.32% [1] - The basic earnings per share were reported at 1.38 yuan [1]